We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Medica 2024 Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Danaher Corporation to Acquire Phenomenex

By LabMedica International staff writers
Posted on 14 Oct 2016
Danaher Corporation (Washington, D.C., USA) will acquire Phenomenex Inc., (Torrance, CA, USA), a privately held manufacturer and distributor of high-value consumables for the separation sciences, including proprietary chromatography consumables for the liquid and gas chromatography market.

Phenomenex has more than 7,000 products supporting various applications in drug discovery and development, clinical research, forensic toxicology, petrochemical, environmental analysis and food safety. Following the acquisition, it will operate as a standalone operating company, retaining the Phenomenex brand, its personnel and site locations.

“Phenomenex is a widely recognizable brand that we are proud to say is highly respected and well established as providing high-quality consumables to the scientific community worldwide,” said Fasha Mahjoor, CEO, Phenomenex. “Joining Danaher will allow us to maintain the high pace of innovation that our customers and international distributors have come to expect from us. This is our opportunity to further expand our R&D activities, benefit our customers with a more diversified product portfolio and reinforce our market leadership.”

“We are thrilled to have Phenomenex join Danaher’s life sciences portfolio of businesses, which include SCIEX, Beckman Coulter Life Sciences, Pall, Leica Microsystems and Molecular Devices,” said Dan Daniel, Executive Vice President, Danaher. “Phenomenex is a strong business characterized by high growth rates and margins and excellent growth prospects driven by increasing analytical testing needs in the health, research and environmental segments. The Danaher Business System (DBS) has a strong track record of helping businesses rapidly scale operations and create long-term customer value. We look forward to supporting the Phenomenex team in leveraging DBS tools for growth and welcoming them to our Life Sciences team.”

Related Links:
Danaher
Phenomenex

New
Gold Member
Syphilis Screening Test
VDRL Antigen MR
Antipsychotic TDM AssaysSaladax Antipsychotic Assays
New
Automatic Biochemistry Analyzer
Audmax 180 Evolution
New
Human Insulin CLIA
Human Insulin CLIA Kit

Latest Industry News

Bio-Techne and ALZpath Partner to Advance Neurodegenerative Disease Research and Treatment

Microbiologics Acquires Diagnostic Quality Controls Manufacturer SensID

Beckman Coulter Partners with BioPorto for Global Distribution of Acute Kidney Injury NGAL Tests